Kapilkumar Patel, MD
Pulmonary Disease · Winston Salem, NCNPI 1356416531
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 66.4% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $14,996 and has fallen 97.4% since, to $385 in 2025.
Across 154 payments — averaging $138.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$14K
- United Therapeutics Corporation$1K
- Transmedics, Inc.$706
- La Jolla Pharmaceutical Company$577
- Astellas Pharma US Inc$573
- Genentech USA, Inc.$572
- plus $3K from 28 others
Across 42 payments — averaging $10,915 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$383K
- Transmedics, Inc.$31K
- Sanofi US Services Inc.$31K
- AbbVie$14K
- Vivus LLC$405
What the payments were for
- Consulting fees$2121%
- Speaking & faculty fees$12,14057%
- Travel & lodging$2,63412%
- Food & beverage$6,23029%
- Education$740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 17 | $14,144 |
| United Therapeutics Corporation | 21 | $1,443 |
| Transmedics, Inc. | 1 | $706 |
| La Jolla Pharmaceutical Company | 6 | $577 |
| Astellas Pharma US Inc | 17 | $573 |
| Genentech USA, Inc. | 10 | $572 |
| Boehringer Ingelheim | 8 | $421 |
| Genentech, Inc. | 3 | $420 |
| Paragonix Technologies, Inc. | 4 | $396 |
| Actelion Pharmaceuticals US, Inc. | 12 | $224 |
| Johnson & Johnson | 6 | $204 |
| ANI Pharmaceuticals, Inc. | 8 | $187 |
| Mallinckrodt Hospital Products Inc. | 4 | $168 |
| Abiomed | 2 | $151 |
| Vapotherm Inc | 3 | $147 |
| AstraZeneca | 1 | $127 |
| Organox Ltd | 1 | $127 |
| Shionogi Inc | 6 | $118 |
| Melinta Therapeutics, LLC | 4 | $98 |
| Insmed, Inc. | 2 | $67 |
| Chiesi USA, Inc. | 3 | $59 |
| Liquidia Technologies, Inc. | 1 | $56 |
| Merck | 3 | $51 |
| Boston Scientific | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $36 |
| Livanova USA, Inc. | 1 | $29 |
| Ambu Inc. | 1 | $22 |
| Vertex | 1 | $22 |
| Invivyd Inc | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $20 |
| Atricure, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Getinge USA Sales, LLC | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,289 in reported general payments places this provider in the 85th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 160 | $4,168,942 |
| PrevymisLetermovir | 114 | $794,023 |
| OfevNintedanib Esylate | 49 | $608,376 |
| CreonLipase/Protease/Amylase | 102 | $537,438 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 38 | $306,729 |
| SymdekoTezacaftor/Ivacaftor | 11 | $257,048 |
| ZenpepLipase/Protease/Amylase | 29 | $239,638 |
| CaystonAztreonam Lysine | 18 | $209,191 |
| CresembaIsavuconazonium Sulfate | 25 | $181,475 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 17 | $170,474 |
| Tobi PodhalerTobramycin | 13 | $136,903 |
| Atovaquone | 175 | $114,369 |
| EliquisApixaban | 86 | $86,648 |
| Itraconazole | 163 | $66,864 |
| ForteoTeriparatide | 15 | $60,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta, Symdeko | $22 | $4,425,990171 claims |
| MerckPrevymis, Januvia | $51 | $809,132140 claims |
| Boehringer IngelheimOfev | $421 | $608,37649 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $36 | $306,72938 claims |
| GileadCayston | $14,144 | $209,19118 claims |
| Astellas Pharma US IncCresemba | $573 | $181,47525 claims |
| Mylan Specialty L.p.Tobi Podhaler | $19 | $136,90313 claims |
| AstraZenecaLokelma, Symbicort | $127 | $8,89033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Winston Salem
- Eugene BleeckerWinston Salem$357K
- Jill OharWinston Salem$226K
- Stephen PetersWinston Salem$59K
- Jessica FieldWinston Salem$55K
- Wendy MooreWinston Salem$48K
- Christina BellingerWinston Salem$32K
- Chad MarionWinston Salem$17K
- Andrew NamenWinston Salem$16K
- Victor OrtegaWinston Salem$15K
- Michael PritchettPinehurst$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.